Phase I/II Trial Evaluation of Radiol... - Advanced Prostate...

Advanced Prostate Cancer

21,581 members27,011 posts

Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant PCa with [161Tb]Tb-PSMA-I&T

Maxone73 profile image
8 Replies

and it's supposed to do a better job than Lutetium (Pluvicto)

But keep an eye also on 64 Cu SAR Bispsma, which had some incredible results, and of course Actinium....honestly on paper they all seem to be better than Lutetium, well, after all we are evolving...

urotoday.com/recent-abstrac...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Cenerus profile image
Cenerus

TB-161 does look really interesting. Unlike Lutetium-177 it gives off high LET auger electrons that can act over short distances that should kill micromets which is the main reason lutetium isn't durable and is just a palliative. It's also much easier to produce than lutetium, so should be cheaper and more plentiful. I'm kind of surprised that it didn't get looked at before lutetium-177 given its better overall performance. If this or Actinium or Astatine finally reach the market, they'll make lutetium obsolete.

Maxone73 profile image
Maxone73 in reply to Cenerus

I know that there are always exceptiona responders...but here is a gift for you (in case you haven't read about this before): guoncologynow.com/post/comp... 😀

Cenerus profile image
Cenerus in reply to Maxone73

I saw that about CU-67. And when you look at CU-67 next to TB-161, the numbers for TB-161 look much more impressive at the level of small volumes down around 5-10 microns where single cells in micrometastasis live.

Maxone73 profile image
Maxone73 in reply to Cenerus

Even better then!

rfgaus profile image
rfgaus

With low SE's and high efficacy to destroy cancer at the cellular level, it would be nice to see these novel Radiogland treatments approved for earlier use in Standard of Care Protocols. Having to go through and fail palliative ADT and Chemo treatments with all their physically destructive SE's to get to something effective is frustrating.

V10fanatic profile image
V10fanatic

"positive disease on [68Ga]Ga-PSMA-11 or [18F]DCFPyL PET/CT (SUVmax ≥ 20); no sites of discordance on [18F]FDG PET/CT"

Yet another new treatment path that won't work for me :-(

Maxone73 profile image
Maxone73 in reply to V10fanatic

Why???

V10fanatic profile image
V10fanatic in reply to Maxone73

My last round of PSMA-PETs came back clear, yet an FDG-PET showed 4 mets.

Not what you're looking for?

You may also like...

Lu-177-PSMA-I&T for low volume Metastatic Castration-Resistant Prostate Cancer

anyone familiar with Lu-177-PSMA-I&T for Metastatic Castration-Resistant ogliometastatic spine mets?

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing

om-veru-111-phase-1b-2-trial-in-men-with-metastatic-castration-resistant-prostate-cancer-advancing-t

Update: FDA grants Priority Review for 177Lu-PSMA-617 for patients with metastatic castration-resistant

targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant...

Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer: some options

ment-after-progression-in-metastatic-castration-resistant-prostate-cancer

Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant PC

Anyone have any experience with this clinical trial? If my PSA continues to increase my doctor is...